Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Bone Marrow Transplantation

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/bmt.2011.9PMID 21358693
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Physicians' Desk Reference

  2014cited by this paper
• Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data

  2011cited by this paper
• The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF

  2011cited by this paper
• Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment

  2010cited by this paper
• Meeting the Unmet Needs in Anticoagulant Therapy

  2010cited by this paper
• A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment.

  2010cited by this paper
• Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.

  2009cited by this paper
• Cost Analysis of Mobilization and Autologous Transplantation in Patients Who Received AMD 3100 after Failing Standard Mobilization.

  2008cited by this paper
• AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data

  2008cited by this paper
• Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure

  2005cited by this paper
• Impact of different strategies of second-line stem cell harvest on the outcome of autologous transplantation in poor peripheral blood stem cell mobilizers

  2005cited by this paper
• Analysis of remobilization success in patients undergoing autologous stem cell transplants who fail an initial mobilization: risk factors, cytokine use and cost

  2004cited by this paper
• Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant

  2004cited by this paper
• High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

  2003cited by this paper
• Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation.

  2001cited by this paper
• Pharmacokinetics and Safety of AMD-3100, a Novel Antagonist of the CXCR-4 Chemokine Receptor, in Human Volunteers

  2000cited by this paper
• Myopericarditis caused by cyclophosphamide used to mobilize peripheral blood stem cells in a myeloma patient with renal failure

  2000cited by this paper
• Second Attempts at Mobilization of Peripheral Blood Stem Cells in Patients with Initial Low CD34+ Cell Yields

  1998cited by this paper

• Autologous stem cell transplantation can potentially reverse dialysis dependence in patients with myeloma: Report of two cases and practical considerations.

  2024cites this paper
• Low non‐relapse mortality and good haematological and renal responses after autologous haematopoietic stem cell transplantation in multiple myeloma patients with renal insufficiency at transplant: A prospective Société Francophone de Greffe de Moelle‐Thérapie Cellulaire observational study

  2023cites this paper
• Salvage Chemotherapy Followed by Autologous Stem-Cell Transplantation Using Targeted Busulfan for Refractory Diffuse Large B-Cell Lymphoma With Dialysis-Dependent End-Stage Renal Disease.

  2019cites this paper
• The Biological and Clinical Relevance of G Protein-Coupled Receptors to the Outcomes of Hematopoietic Stem Cell Transplantation: A Systematized Review

  2019cites this paper
• Stem cell mobilization in patients with dialysis‐dependent multiple myeloma: Report of the Polish Myeloma Study Group

  2018cites this paper
• Autologous Stem Cell Mobilization and Collection.

  2016cites this paper
• Stem cell mobilization in lymphoma patients

  2015cites this paper
• Multiple Myeloma and Renal Failure

  2015cites this paper
• A plerixafor-based strategy allows adequate hematopoietic stem cell collection in poor mobilizers: results from the Canadian Special Access Program

  2014cites this paper
• Peripheral Blood Progenitor Cells Mobilization in Patients with Multiple Myeloma

  2014cites this paper
• Autologous stem cell transplantation in the management of multiple myeloma

  2014cites this paper
• Plerixafor and G-CSF for autologous stem cell mobilization in AL amyloidosis

  2014cites this paper
• Regulatory Systems in Bone Marrow for Hematopoietic Stem/Progenitor Cells Mobilization and Homing

  2013cites this paper
• Current Clinical Indications for Plerixafor

  2013cites this paper
• Die retrospektive Analyse der Wirkung von patientenspezifischen Parametern auf die benötigte Apheresenanzahl und den CD34 + -Ertrag von autologen Stammzellspendern

  2012cites this paper
• Mobilization of Hematopoietic Stem Cells in Patients with Multiple Myeloma Utilizing Growth Factor Combined with Plerixafor

  2012cites this paper
• Stem Cell Mobılızatıon in Multıple Myeloma

  2012cites this paper
• Plerixafor in AL amyloidosis: improved graft composition and faster lymphocyte recovery after auto-SCT in patient with end-stage renal-disease

  2012cites this paper
• Unsuccessful stem cell remobilization for autologous transplantation is predicted by renal impairment and a stem cell yield ⩽0.5 × 106 CD34+ cells/kg at first mobilization

  2012cites this paper
• Novel agents and approaches for stem cell mobilization in normal donors and patients

  2012cites this paper
• Plerixafor

  2011cites this paper
• Novel strategies for blood stem cell mobilization: special focus on plerixafor

  2011cites this paper